A new frontier in oncology: Understanding the landscape of cancer vaccines

Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes. Key barriers to vaccine efficacy include tumor immune evasion, heterogeneity and the suppressive tumor microenvironment; combination therapies with checkpoint inhibitors or chemotherapy are evaluated for their potential to overcome these challenges. Despite promising trials, challenges persist in neoantigen selection, biomarker development, regulatory approval and scalable vaccine manufacturing. Data on current global utilization, approved indications and coverage disparities particularly in low and middle-income countries are presented. Furthermore, the cancer vaccine market is segmented by disease type, platform technology and region, with rising investments in personalized mRNA platforms and combined immunotherapies driving growth. In conclusion, cancer vaccines offer a less toxic, more precise approach to cancer prevention and treatment. Continued innovation, global collaboration, and infrastructure development are essential to realizing their full potential in improving patient outcomes and reducing the global cancer burden.